Crescent Biopharma, Inc. (CBIO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Crescent Biopharma, Inc. (CBIO) closed at USD 12.58 on 2026-10-14, a change of +0.6 % over the past year, with a market capitalization of USD 463.59M.

Crescent Biopharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Crescent Biopharma, Inc. key figures

Previous close

USD 12.58 (2026-10-14)

1-year change

+0.6 %

Market cap

USD 463.59M

Enterprise value

USD 368M

P/E ratio (trailing)

-1.64

P/E ratio (forward)

-4.75

EPS (trailing)

-7.63

EPS (forward)

-2.63

PEG ratio

n/a

Price to book

2.62

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.78

Employees

69

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Crescent Biopharma, Inc.

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Crescent Biopharma, Inc. and compare it with other stocks.